first paper on dexmedetomidine was published in 2011; since then, more than 40 papers on this agent have been published in the KJA.
presynaptic inhibition in the locus coeruleus, or to a reduction in sympathetic outflow, which may in turn trigger postoperative nausea and vomiting.
Moon et al. [8] presented a case report entitled "Non-intubated thoracoscopic surgery for decortication of empyema under thoracic epidural anesthesia. " In this case, video-assisted thoracoscopic surgery was performed in a non-intubated patient. During surgery, thoracic epidural anesthesia and target-controlled infusion of propofol and remifentanil were maintained. In addition, dexmedetomidine was continuously infused at a rate of 0.4 μg/kg/h. Although this regimen may appear somewhat reckless, the patient recovered fully without complications.
Taken together, these studies suggest that dexmedetomidine could be assistive in anesthesiologic practice in the near future. However, in addition to its possible benefits, certain drawbacks of dexmedetomidine must also be noted. First, bradycardia and hypotension could result from rapid infusion at higher doses, during or even after surgical operation. Furthermore, perioperative bradycardia and hypotension may be severe enough to require treatment. A final drawback of dexmedetomidine is delayed awakening; when it is used for a short surgery, delayed awakening and postoperative sedation could be problematic for anesthesiologists.
In summary, if anesthesiologists use dexmedetomidine only for carefully selected patients, they may find it helpful. However, dexmedetomidine may also produce effects that are problematic for anesthesiologists.
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